WO2022072811A1 - Pharmaceutical formulations for treating diseases mediated by kdm1a - Google Patents

Pharmaceutical formulations for treating diseases mediated by kdm1a Download PDF

Info

Publication number
WO2022072811A1
WO2022072811A1 PCT/US2021/053141 US2021053141W WO2022072811A1 WO 2022072811 A1 WO2022072811 A1 WO 2022072811A1 US 2021053141 W US2021053141 W US 2021053141W WO 2022072811 A1 WO2022072811 A1 WO 2022072811A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
compound
amount
capsules
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/053141
Other languages
English (en)
French (fr)
Inventor
Amy TAPPER
Cassandra Celatka
Patricia SOULLIAC
Parag VED
Namrata VORA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imago Biosciences Inc
Original Assignee
Imago Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112023005987A priority Critical patent/BR112023005987A2/pt
Priority to MX2023003783A priority patent/MX2023003783A/es
Priority to EP21876583.2A priority patent/EP4221704B1/en
Priority to JP2023519794A priority patent/JP7848195B2/ja
Priority to AU2021351536A priority patent/AU2021351536A1/en
Priority to KR1020237014383A priority patent/KR20230079151A/ko
Application filed by Imago Biosciences Inc filed Critical Imago Biosciences Inc
Priority to CN202180068111.4A priority patent/CN116367831A/zh
Priority to CA3193661A priority patent/CA3193661A1/en
Publication of WO2022072811A1 publication Critical patent/WO2022072811A1/en
Priority to US18/188,578 priority patent/US20230293495A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the 50 mg capsules were relatively stable as compared to the 35 mg tablets.
  • Table 47 Stability profile for 5 mg tablets, control formulation manufactured via direct blend.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/US2021/053141 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a Ceased WO2022072811A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2023003783A MX2023003783A (es) 2020-10-01 2021-10-01 Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.
EP21876583.2A EP4221704B1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a
JP2023519794A JP7848195B2 (ja) 2020-10-01 2021-10-01 Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤
AU2021351536A AU2021351536A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a
KR1020237014383A KR20230079151A (ko) 2020-10-01 2021-10-01 Kdm1a 에 의해 매개되는 질환 치료용 약학 제형
BR112023005987A BR112023005987A2 (pt) 2020-10-01 2021-10-01 Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade
CN202180068111.4A CN116367831A (zh) 2020-10-01 2021-10-01 用于治疗由kdm1a介导的疾病的药物配制品
CA3193661A CA3193661A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a
US18/188,578 US20230293495A1 (en) 2020-10-01 2023-03-23 Pharmaceutical formulations for treating diseases mediated by kdm1a

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
US63/086,353 2020-10-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/188,578 Continuation US20230293495A1 (en) 2020-10-01 2023-03-23 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (1)

Publication Number Publication Date
WO2022072811A1 true WO2022072811A1 (en) 2022-04-07

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/053141 Ceased WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Country Status (10)

Country Link
US (1) US20230293495A1 (https=)
EP (1) EP4221704B1 (https=)
JP (1) JP7848195B2 (https=)
KR (1) KR20230079151A (https=)
CN (1) CN116367831A (https=)
AU (1) AU2021351536A1 (https=)
BR (1) BR112023005987A2 (https=)
CA (1) CA3193661A1 (https=)
MX (1) MX2023003783A (https=)
WO (1) WO2022072811A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
US20160237043A1 (en) * 2015-02-12 2016-08-18 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
WO2018035259A1 (en) * 2016-08-16 2018-02-22 Imago Biosciences, Inc. Methods and processes for the preparation of kdm1a inhibitors
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
WO2021118996A1 (en) * 2019-12-09 2021-06-17 Imago Biosciences, Inc. Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
TW201431552A (zh) 2008-07-28 2014-08-16 Takeda Pharmaceutical 醫藥組成物
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
RU2627471C2 (ru) * 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
US20160237043A1 (en) * 2015-02-12 2016-08-18 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
WO2018035259A1 (en) * 2016-08-16 2018-02-22 Imago Biosciences, Inc. Methods and processes for the preparation of kdm1a inhibitors
WO2021118996A1 (en) * 2019-12-09 2021-06-17 Imago Biosciences, Inc. Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4221704A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Also Published As

Publication number Publication date
CN116367831A (zh) 2023-06-30
EP4221704A1 (en) 2023-08-09
KR20230079151A (ko) 2023-06-05
MX2023003783A (es) 2023-04-26
EP4221704A4 (en) 2024-11-06
BR112023005987A2 (pt) 2023-05-02
EP4221704B1 (en) 2025-09-24
JP2023544327A (ja) 2023-10-23
US20230293495A1 (en) 2023-09-21
JP7848195B2 (ja) 2026-04-20
CA3193661A1 (en) 2022-04-07
AU2021351536A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
EP1441713B1 (en) Modified release tamsulosin tablets
RU2405540C1 (ru) Таблетка с высоким содержанием лекарственного препарата
US9962390B2 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
US7943170B2 (en) Sustained release paracetamol containing compositions
AU2018326596B2 (en) High concentration dosage forms of pridopidine
KR20090016611A (ko) 메만틴의 약학 조성물
WO2019149917A1 (en) A pharmaceutical composition comprising metamizole, drotaverine, and caffeine
US20020123503A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
US9572806B2 (en) Elution-stabilized preparation
CN103717209B (zh) 速释的含普拉格雷的稳定的口服药物组合物
EP1810676A1 (en) Levetiracetam formulations and methods for their manufacture
CN108125918B (zh) 依维莫司药物组合物
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
KR20180036633A (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
EA051661B1 (ru) Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a
EP4725474A1 (en) A solid composition of eliglustat
EP4736851A1 (en) Levodopa-benserazide hydrochloride composition and preparation therefor
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound
JP2025524357A (ja) 多数の顆粒
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide
CN108721241A (zh) 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法
KR20200113116A (ko) 데페라시록스를 포함하는 필름코팅정제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21876583

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3193661

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023519794

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023005987

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237014383

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112023005987

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230330

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021351536

Country of ref document: AU

Date of ref document: 20211001

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021876583

Country of ref document: EP

Effective date: 20230502

WWG Wipo information: grant in national office

Ref document number: 2021876583

Country of ref document: EP